Skip to main content

Table 4 Prognostic factors according to subgroup analysis

From: Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses

Variables

Luminal A

Luminal B

HER2

TNBC

HR

95 % CI

P

HR

95 % CI

P

HR

95 % CI

P

HR

95 % CI

P

Age

            

  ≤ median

0.477

0.078–2.907

0.422

0.646

0.207–2.019

0.453

0.616

0.188–2.016

0.423

0.597

0.168–2.115

0.424

  > median

1

  

1

  

1

  

1

  

Menopausal status

            

 Premenopausal

0.092

0.009–0.906

0.041

0.875

0.282–2.727

0.818

0.482

0.132–1.754

0.268

0.741

0.214–2.558

0.635

 Postmenopausal

1

  

1

  

1

  

1

  

pCR

 

-

 

0.039

0.000–46.767

0.370

0.360

0.047–2.773

0.327

0.420

0.053–3.323

0.411

vs non-pCR

   

1

  

1

  

1

  

AJCC response

            

 CR plus PR

0.078

0.008–0.778

0.030

0.157

0.050–0.499

0.002

0.221

0.058–0.838

0.026

0.219

0.061–0.783

0.020

 NR

1

  

1

  

1

  

1

  

Pathologic Stage

            

 yp0,I

0.517

0.247–1.081

0.080

0.160

0.021–1.238

0.079

0.162

0.036–0.732

0.018

0.182

0.038–0.861

0.032

 ypII, III, IV

1

  

1

  

1

  

1

  

Surgery

            

 BCS

0.414

0.069–2.493

0.336

0.329

0.101–1.071

0.065

0.296

0.081–1.081

0.065

0.930

0.240–3.660

0.917

 Mastectomy

1

  

1

  

1

  

1

  
  1. pCR pathologic complete response, CR complete response, PR partial response, NR no response, BCS breast conserving surgery, HER2 human epidermal growth factor receptor 2, TNBC triple negative breast cancer, HR hazard ratio, 95 % CI 95 % confidence interval, P p-value